Stable angina pectoris: Antianginal therapies and future directions

Nature Reviews Cardiology

Volumn 9, Issue 1, 2012, Pages 40-52

  Chaitman, Bernard R ^a   Laddu, Abhay A ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A ACYLTRANSFERASE; ALLOPURINOL; AMLODIPINE; ANTIANGINA PECTORIS AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CYTOCHROME P450 3A4; DILTIAZEM; FELODIPINE; IVABRADINE; LABETALOL; NICARDIPINE; NICORANDIL; NIFEDIPINE; NITRATE; RANOLAZINE; TRIMETAZIDINE; VASCULOTROPIN; VASOPEPTIDASE INHIBITOR; VERAPAMIL;

CONSTIPATION; DIZZINESS; DRUG MEGADOSE; ELECTROCARDIOGRAPHY; FOLLOW UP; GLUCOSE OXIDATION; HEART ARRHYTHMIA; HEART CONTRACTION; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HUMAN; LONG QT SYNDROME; NAUSEA; OXYGEN CONSUMPTION; PRIORITY JOURNAL; QUALITY OF LIFE; REVASCULARIZATION; REVIEW; STABLE ANGINA PECTORIS; SYSTOLIC BLOOD PRESSURE; VISUAL DISORDER;

ANGINA, STABLE; ANGIOGENESIS INHIBITORS; CALCIUM CHANNEL BLOCKERS; HUMANS; PRACTICE GUIDELINES AS TOPIC; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 83655167300     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2011.129     Document Type: Review

References (111)

1. Gibbons, R. J. et al. ACC/AHA 2002 guideline update for the management of patients with stable angina-summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Chronic Stable Angina). Circulation 107, 149-158 (2003). (Pubitemid 36070948)
2. Fraker, T. D. Jr et al. 2007 chronic angina focused update of the ACC/AHA 2002 Guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 Guidelines for the management of patients with chronic stable angina. Circulation 116, 2762-2772 (2007). (Pubitemid 350291248)
3. Fox, K. et al. Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur. Heart J. 27, 1341-1381 (2006). (Pubitemid 43998110)
4. Smith, S. C. et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. Endorsed by the National Heart, Lung, and Blood Institute. Circulation 113, 2363-2372 (2006).
5. Boden, W. E. et al. Optimal medical therapy with or without PCI for stable coronary disease. N. Engl. J. Med. 356, 1503-1516 (2007). (Pubitemid 46588415)
6. Maron, D. J. et al. Intensive multifactorial intervention for stable coronary artery disease: optimal medical therapy in the COURAGE trial. J. Am. Coll. Cardiol. 55, 1348-1358 (2010).
7. The BARI 2D Study Group. A randomized trial of therapy for type 2 diabetes and coronary artery disease. N. Engl. J. Med. 360, 2503-2515 (2009).
8. Chaitman, B. R. et al. The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease. Impact of treatment strategy on cardiac mortality and myocardial infarction. Circulation 120, 2529-2540 (2009).
9. Chaitman, B. R., Hadid, M. & Laddu, A. A. Choice of initial medical therapy vs. prompt coronary revascularization in patients with type 2 diabetes and stable ischemic coronary disease with special emphasis on the BARI 2D trial results. Curr. Opin. Cardiol. 25, 597-602 (2010).
10. Simoons, M. L. & Windecker, S. Chronic stable coronary artery disease: drugs vs. revascularization. Eur. Heart J. 31, 530-541 (2010).
11. Bakris, G. L. et al. Metabolic effects of carvedilol vs. metoprolol in patients with type 2 diabetes mellitus and hypertension. A randomized controlled trial. JAMA 292, 2227-2236 (2004). (Pubitemid 39473160)
12. Weiss, R. et al. Effectiveness of three different doses of carvedilol for exertional angina. Carvedilol Angina Study Group. Am. J. Cardiol. 82, 927-931 (1998). (Pubitemid 28480776)
13. van der Does, R. et al. Comparison of safety and efficacy of carvedilol and metoprolol in stable angina pectoris. Am. J. Cardiol. 83, 643-649 (1999). (Pubitemid 29115431)
14. Hauf-Zachariou, U. et al. Carvedilol versus verapamil in chronic stable angina: a multicentre trial. Eur. J. Clin. Pharmacol. 52, 95-100 (1997). (Pubitemid 27239592)
15. Bangalore, S., Parkar, S., Grossman, E. & Messerli, F. H. A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am. J. Cardiol. 100, 1254-1262 (2007). (Pubitemid 47498283)
16. Elliott, W. J. & Meyer, P. M. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 269, 201-207 (2007). (Pubitemid 46111014)
17. Kobusiak-Prokopowicz, M. et al. Impact of nebivolol on levels of serum nitric oxide, plasma von Willebrand factor and exercise stress testing parameters in hypertensive and ischemic heart disease patients. Cardiol. J. 15, 162-168 (2008). (Pubitemid 351721978)
18. Gumbrielle, T. et al. Efficacy, safety and duration of nitrate-free interval to prevent tolerance to transdermal nitroglycerin in effort angina. Eur. Heart J. 13, 671-678 (1992).
19. Chaitman, B. R. & Sano, J. Novel therapeutic approaches to treating chronic angina in the setting of chronic ischemic heart disease. Clin. Cardiol. 30 (Suppl. 1), I25-I30 (2007).
20. Ciapponi, A., Pizzarro, R. & Harrison, J. Trimetazidine for stable angina. Cochrane Database of Systematic Reviews, Issue 4, Art. No.: CD003614. doi:10.1002/14651858.CD003614.pub2 (2005).
21. Ribeiro, L. W., Ribeiro, J. P., Stein, R., Leitao, C. & Polanczyk, C. A. Trimetazidine added to combined hemodynamic antianginal therapy in patients with type 2 diabetes: a randomized crossover trial. Am. Heart J. 154, 78.e1-78.e7 (2007).
22. MacInnes, A. et al. The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ. Res. 93, e26-e32 (2003).
23. Marazzi, G. et al. Effect of fatty acid inhibition on silent and symptomatic myocardial ischemic in diabetic patients with coronary artery disease. Int. J. Cardiol. 120, 79-84 (2007). (Pubitemid 47002010)
24. IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact of Nicorandil of Angina (IONA) randomised trial. Lancet 359, 1269-1275 (2002).
25. IONA Study Group. Determinants of coronary events in patients with stable angina: results from the Impact of Nicorandil in Angina Study. Am. Heart J. 150, 689.e1-689.e9 (2005).
26. Simpson, D. & Wellington, K. Nicorandil: a review of its use in the management of stable angina pectoris, including high-risk patients. Drugs 64, 1941-1955 (2004). (Pubitemid 39263662)
27. Hanai, Y., Mita, M., Hishinuma, S. & Shoji, M. Systematic review on the short-term efficacy and safety of nicorandil for stable angina pectoris in comparison with those of β-blockers, nitrates and calcium antagonists. J. Pharmaceut. Soc. Japan 130, 1549-1563 (2010).
28. Chaitman, B. R. Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions. Circulation 113, 2462-2472 (2006). (Pubitemid 43948054)
29. Antzelevitch, C. et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 110, 904-910 (2004). (Pubitemid 39136212)
30. Makielski, J. C. & Valdivia, C. R. Ranolazine and late cardiac sodium current-a therapeutic target for angina, arrhythmia and more? Br. J. Pharmacol. 148, 4-6 (2006). (Pubitemid 43675594)
31. Chaitman, B. R. et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J. Am. Coll. Cardiol. 43, 1375-1382 (2004). (Pubitemid 38496341)
32. Chaitman, B. R. et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina. JAMA 291, 309-316 (2004). (Pubitemid 38101603)
33. Stone, P. H., Gratsiansky, N. A., Blokhin, A., Huang, I. Z. & Meng, L. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J. Am. Coll. Cardiol. 48, 566-755 (2006).
34. Stone, P. H. et al. The anti-ischemic mechanism of action of ranolazine in stable ischemic heart disease. J. Am. Coll. Cardiol. 56, 934-942 (2010).
35. Venkataraman, R., Belardinelli, L., Blackburn, B., Heo, J. & Iskandrian, A. E. A study of the effects of ranolazine using automated quantitative analysis of serial myocardial perfusion images. J. Am. Coll. Cardiol. Cardiovasc. Imaging 2, 1301-1309 (2009).
36. US National Library of Medicine. Study the Effects of Ranolazine on Myocardial Perfusion Assessed by Serial Quantitative Exercise SPECT Imaging. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01221272 (2011).
37. Timmis, A. D., Chaitman, B. R. & Crager, M. Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur. Heart J. 27, 42-48 (2006). (Pubitemid 41785931)
38. Morrow, D. A. et al. Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial. Circulation 119, 2032-2039 (2009).
39. Chisholm, J. W. et al. Effect of ranolazine on A1C and glucose levels in hyperglycemic patients with non-ST elevation acute coronary syndrome. Diabetes Care 33, 1163-1168 (2010).
40. Ning, Y. et al. Ranolazine increases β-cell survival and improves glucose homeostasis in low dose STZ-induced diabetes in mice. J. Pharmacol. Exp. Ther. 337, 50-58 (2011).
41. Morrow, D. A. et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes. The MERLIN-TIMI 36 randomized trial. JAMA 297, 1775-1783 (2007). (Pubitemid 46658646)
42. Mega J. L. et al. Clinical features and outcomes of women with unstable ischemic heart disease. Observations from Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36). Circulation 121 1809-1817 (2010).
43. Morrow, D. A. et al. B-type natriuretic peptide and the effect of ranolazine in patients with non-ST-segment elevation acute coronary syndromes. Observations from the MERLIN-TIMI 36 (Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 36) trial. J. Am. Coll. Cardiol. 55, 1189-1196 (2010).
44. Wilson, S. R. et al. Efficacy of ranolazine in patients with chronic angina. Observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 trial. J. Am. Coll. Cardiol. 53, 1510-1516 (2009).
45. Scirica, B. M. et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non-ST-segment-elevation acute coronary syndrome. Results from the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation 116, 1647-1652 (2007). (Pubitemid 47537839)
46. Scirica, B. M. et al. Relationship between nonsustained ventricular tachycardia after non-ST-elevation acute coronary syndrome and sudden cardiac death. Observations from the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation 122, 455-462 (2010).
47. Scirica, B. M. et al. Ischemia detected on continuous electrocardiography after acute coronary syndrome. Observations from the MERLIN-TIMI 36 (Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 36) trial. J. Am. Coll. Cardiol. 53, 1411-1421 (2009).
48. US National Library of Medicine. Ranolazine Implantable Cardioverter-Defibrillator Trial (RAID). ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01215253 (2010).
49. Burashnikov, A., Di Diego, J. M., Zygmunt, A. C., Belardinelli, L. & Antzelevitch, C. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation. Differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation 116, 1449-1457 (2007). (Pubitemid 47480635)
50. Sossalla, S. et al. Altered Na+ currents in atrial fibrillation. Effects of ranolazine on arrhythmias and contractility in human atrial myocardium. J. Am. Coll. Cardiol. 55, 2330-2342 (2010).
51. Sicouri, S., Burashnikov, A., Belardinelli, L. & Antzelevitch, C. Synergistic electrophysiologic and antiarrhythmic effects of the combination of ranolazine and chronic amiodarone in canine atria. Circ. Arrhythm. Electrophysiol. 3, 88-95 (2010).
52. Moss, A. J. et al. Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome. J. Cardiovasc. Electrophysiol. 19, 1289-1293 (2008).
53. Antoons, G. et al. Late Na+ current inhibition by ranolazine reduces torsades de pointes in the chronic atrioventricular block dog model. J. Am. Coll. Cardiol. 55, 801-809 (2010).
54. Dhalla, A. K. et al. Ranolazine, an antianginal agent, markedly reduces ventricular arrhythmias induced by ischemia and ischemia-reperfusion. Am. J. Physiol. Heart Circ. Physiol. 297, H1923-H1929 (2009).
55. Hwang, H. et al. Ranolazine as a cardioplegia additive improves recovery of diastolic function in isolated rat hearts. Circulation 120, S16-S21 (2009).
56. Lindegger, N., Hagen, B., Marks, A. R., Lederer, W. J. & Kass, R. S. Diastolic transient inward current in long QT syndrome type 3 is caused by Ca2+ overload and inhibited by ranolazine. J. Mol. Cell. Cardiol. 47, 326-334 (2009).
57. Ma, A. et al. A pilot study of ranolazine in patients with intermittent claudication. Int. Angiol. 25, 361-369 (2006). (Pubitemid 46350993)
58. Miles, R. H., Passman, R. & Murdoch, D. K. Comparison of effectiveness and safety of ranolazine versus amiodarone for preventing atrial fibrillation after coronary artery bypass grafting. Am. J. Cardiol. 108, 673-676 (2011).
59. Jacobshagen, C., Belardinelli, L., Hasenfuss, G. & Maier, L. S. Ranolazine for the treatment of heart failure with preserved ejection fraction: background, aims and design of the RALI-DHF study. Clin. Card. 34, 426-432 (2011).
60. Rich, M. W., Crager, M. & McKay, C. R. Safety and efficacy of extended-release ranolazine in patients aged 70 years or older with chronic stable angina pectoris. Am. J. Geriatr. Cardiol. 16, 216-221 (2007).
61. DiFrancesco, D. The role of the funny current in pacemaker activity. Circ. Res. 106, 434-446 (2010).
62. Baruscotti, M., Barbuti, A. & Bucchi, A. The cardiac pacemaker current. J. Mol. Cell. Cardiol. 48, 55-64 (2010).
63. Savelieva, I. & Camm, A. J. If inhibition with ivabradine: electrophysiological effects and safety. Drug Safety 31, 95-107 (2008). (Pubitemid 351175614)
64. Fernandez, S. F., Tandar, A. & Boden, W. E. Emerging medical treatment for angina pectoris. Expert Opin. Emerging Drugs 15, 283-298 (2010).
65. Tardif, J. C. et al. Efficacy of the If current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur. Heart J.30, 540-548 (2009).
66. Borer, J. S., Fox, K., Jaillon, P. & Lerebours, G. Antianginal and antiischemic effects of ivabradine, an If inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation 107, 817-823 (2003). (Pubitemid 36241038)
67. Tardif, J.-C. et al. Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina. Eur. Heart J. 26, 2529-2536 (2005). (Pubitemid 41677303)
68. Tendera, M., Borer, J. S. & Tardif, J.-C. Efficacy of If inhibition with ivabradine in different subpopulations with stable angina pectoris. Cardiology 114, 116-125 (2009).
69. Demontis, G. C., Gargini, C., Paoli, T. G. & Cervetto, L. Selective Hcn1 channels inhibition by ivabradine in mouse rod photoreceptors. Invest. Ophthalmol. Vis. Sci. 50, 1948-1955 (2009).
70. Fox, K. et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomized controlled trial. Lancet 372, 817-821 (2008).
71. Fox, K. et al. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomized, double-blind, placebo-controlled trial. Lancet 372, 807-816 (2008).
72. Fox, K. et al. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur. Heart J. 30, 2337-2345 (2009).
73. Swedberg, K. et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376, 875-885 (2010).
74. Bohm, M. et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 376, 886-894 (2010).
75. Ferrari, R. A step further with ivabradine: SIGNIfY (Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease). Eur. Heart J. Suppl. 11 (Suppl. D), D19-D27 (2009).
76. Steg, P. G. Heart rate management in coronary artery disease: the CLARIFY registry. Eur. Heart J. Suppl. 11 (Suppl. D), D13-D18 (2009).
77. Dominguez-Rodriguez, A. et al. Randomised, double-blind, placebo-controlled trial of ivabradine in patients with acute coronary syndrome: effects of the If current inhibitor ivabradine on reduction of inflammation markers in patients with acute coronary syndrome-RIVIERA trial study design and rationale. Cardiovasc. Drugs Ther. 23, 243-247 (2009).
78. Trippodo, N. C. et al. Combined inhibition of neutral endopeptidase and angiotensin converting enzyme in cardiomyopathic hamsters with compensated heart failure J. Pharmacol. Exp. Ther. 267, 108-116 (1993). (Pubitemid 23324995)
79. Chaitman, B. R. et al. Antianginal efficacy of omapatrilat in patients with chronic angina pectoris. Am. J. Cardiol. 95, 1283-1289 (2005). (Pubitemid 40719857)
80. Vicari, R. M. et al. Efficacy and safety of fasudil in patients with stable angina: a double-blind, placebo-controlled, phase 2 trial. J. Am. Coll. Cardiol. 46, 1803-1811 (2005). (Pubitemid 41579800)
81. Noman, A., Ang, D. S., Ogston, S., Lang, C. C. & Struthers, A. D. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomized, placebo controlled crossover trial. Lancet 375, 2161-2167 (2010).
82. Khatib, S. Y, Farah, H. & El-Migdadi, F. Allopurinol enhances adenine nucleotide levels and improves myocardial function in isolated hypoxic rat heart. Biochemistry (Mosc.) 66, 328-333 (2001). (Pubitemid 32445803)
83. Grines, C. L. et al. A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. J. Am. Coll. Cardiol. 42, 1339-1347 (2003). (Pubitemid 37267270)
84. Reilly, J. P. et al. Long-term (2-year) clinical events following transthoracic intramyocardial gene transfer of VEGF-2 in no-option patients. J. Interven. Cardiol. 81, 27-31 (2005). (Pubitemid 40468771)
85. Losordo, D. W. et al. Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation 105, 2012-2018 (2002). (Pubitemid 34465261)
86. Losordo, D. W. et al. Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina. A phase I/IIa double-blind, randomized controlled trial. Circulation 115, 3165-3172 (2007). (Pubitemid 47018140)
87. Shantsila, E., Watson, T. & Lip, G. Y. Endothelial progenitor cells in cardiovascular disorders. J. Am. Coll. Cardiol. 49, 741-752 (2007).
88. Henry, T. D. et al. Effects of Ad5FGF-4 in patients with angina: an analysis of pooled data from the AGENT-3 and AGENT-4 trials. J. Am. Coll. Cardiol. 50, 1038-1046 (2007). (Pubitemid 47354223)
89. Ylä-Herttuala, S., Rissanen, T. T., Vajanto, I. & Hartikainen, J. Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine. J. Am. Coll. Cardiol. 49, 1015-1026 (2007). (Pubitemid 46349500)
90. Simons, M. et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: Double-blind, randomized, controlled clinical trial: FGF Initiating RevaScularization Trial (FIRST). Circulation 105, 788-793 (2002). (Pubitemid 34174916)
91. Henry, T. et al. The VIVA trial: Vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation 107, 1359-1365 (2003). (Pubitemid 36350732)
92. Attanasio, S. & Schaer, G. Therapeutic angiogenesis for the management of refractory angina: current concepts. Cardiovasc. Ther. doi:10.1111/j.1755-59222010.00153.x.
93. Grines, C. et al. Angiogenic gene therapy (AGENT) trial in patients with stable angina pectoris. Circulation 105, 1291-1297 (2002). (Pubitemid 34260418)
94. Kastrup, J. et al. Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris: The Euroinject One trial. J. Am. Coll. Cardiol. 45, 982-988 (2005). (Pubitemid 40432426)
95. Gupta, R., Tongers, J. & Losordo, D. W. Human studies of angiogenic gene therapy. Circ. Res. 105, 724-736 (2009).
96. van Ramshorst, J. et al. Intramyocardial bone marrow cell injection for chronic myocardial ischemia: A randomized controlled trial. JAMA 301, 1997-2004 (2009).
97. Lathi, K. G. et al. Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease: anesthetic management and results. Anesth. Analg. 92, 19-25 (2001). (Pubitemid 32039171)
98. Losordo, D. W. et al. Intramyocardial, autologous CD34+ cell therapy for refractory angina. Circ. Res. 109, 428-436 (2011).
99. Tongers, J., Losordo, D. W. & Landmesser, U. Stem and progenitor cell-based therapy in ischaemic heart disease: promise, uncertainties, and challenges. Eur. Heart J. 32, 1197-1206 (2011).
100. Weintraub, W. S. et al. Effect of PCI on quality of life in patients with stable coronary disease. N. Engl. J. Med. 359, 677-687 (2008).
101. Hlatky, M. A. et al. Economic outcomes of treatment strategies for type 2 diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial. Circulation 120, 2550-2558 (2009).
102. Brooks, M. M. et al. Health status after treatment for coronary artery disease and type 2 diabetes mellitus in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial. Circulation 122, 1690-1699 (2010).
103. Velazquez, E. J. et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N. Engl. J. Med. 364, 1607-1616 (2011).
104. Bonow, R. O. et al. Myocardial viability and survival in ischemic left ventricular dysfunction. N. Engl. J. Med. 364, 1617-1625 (2011).
105. Dagenais, G. R. et al. Effects of optimal medical treatment with or without coronary revascularization on angina and subsequent revascularization in patients with type 2 diabetes mellitus and stable ischemic heart disease. Circulation 123, 1492-1500 (2011).
106. Wijeysundera, H. C., Nallamothu, B. K., Krumholz, H. M., Tu, J. V. & Ko, D. T. Meta-analysis: Effects of percutaneous coronary intervention versus medical therapy on angina relief. Ann. Intern. Med. 152, 370-379 (2010).
107. The BARI 2D Study Group et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N. Eng. J. Med. 360, 2503-2515 (2009).
108. Farkouh, M. E. et al. Design of the Future R Evascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM) Trial. Am. Heart J. 155, 215-223 (2008).
109. US National Institutes of Health. PROspective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE). ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01174550 (2010).
110. US National Institutes of Health. Randomized Evaluation of Patients With Stable Angina Comparing Diagnostic Examinations (RESCUE). ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01262625 (2011).
111. ISCHEMIA Trial. ISCHEMIA Trial. International Study of Comparative Health Effectiveness with Medical and Invasive Approaches [online], http://www.ischemiatrial.org/ (2011).